BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) traded down 4.6% during trading on Tuesday . The company traded as low as $2.88 and last traded at $2.88, with a volume of 159,963 shares traded. The stock had previously closed at $3.02.

A number of equities research analysts recently commented on the company. FBR & Co restated a “buy” rating and set a $6.00 price target on shares of BioCryst Pharmaceuticals in a research report on Wednesday, July 6th. Jefferies Group upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research report on Wednesday, June 1st. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Monday, May 9th. Finally, Zacks Investment Research lowered BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, April 11th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company’s stock. BioCryst Pharmaceuticals has an average rating of “Hold” and a consensus price target of $9.70.

The stock has a 50-day moving average of $3.08 and a 200-day moving average of $3.69. The company’s market cap is $212.23 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.08. The firm had revenue of $4.82 million for the quarter, compared to the consensus estimate of $5.42 million. The company’s quarterly revenue was down 29.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.21) EPS. Equities research analysts anticipate that BioCryst Pharmaceuticals Inc. will post ($1.06) earnings per share for the current fiscal year.

Several large investors have added to or reduced their stakes in the stock. Jennison Associates LLC increased its stake in BioCryst Pharmaceuticals by 1.8% in the fourth quarter. Jennison Associates LLC now owns 1,348,563 shares of the biotechnology company’s stock worth $13,917,000 after buying an additional 24,014 shares during the last quarter. Globeflex Capital L P purchased a new position in shares of BioCryst Pharmaceuticals during the fourth quarter valued at approximately $1,241,000. Finally, Morgan Stanley increased its position in shares of BioCryst Pharmaceuticals by 13.9% in the fourth quarter. Morgan Stanley now owns 103,804 shares of the biotechnology company’s stock valued at $1,071,000 after buying an additional 12,646 shares in the last quarter.

BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.